Skip to content
Peptide Atlas
All peptides

Vilon

Tier 3 · Reported use
Also known as KE peptide · Lys-Glu dipeptide

The strongest evidence present is Tier 2 (animal, in-vitro, and mechanistic studies). Nearly all data derive from a single research program (Khavinson's St. Petersburg Institute of Bioregulation and Gerontology), predominantly in Russian-language literature, with little independent Western replication. Efficacy data are dominated by cell-culture and rodent studies plus ex vivo work on aged human lymphocyte chromatin; the only human data are one group's 12-year observational cohort follow-up. There are no randomized controlled human trials and no approved indications.

Half-life
~1.2 h
Routes
Subcutaneous injection · Intramuscular injection · Intravenous (used in PK reporting) · Oral / sublingual (Russian retail; intact-peptide oral bioavailability not demonstrated)
Goals
Immune support / immunomodulation · Longevity / geroprotection · Cancer/tumor prevention research (preclinical) · Anti-inflammatory research
Cost / mg
Not recorded

How it works

Vilon is one of the simplest possible bioregulators — a two-amino-acid peptide (lysine plus glutamic acid) developed within the Soviet-era Khavinson peptide bioregulator program. Its developers propose that, because it is so small, it can slip into the cell nucleus and bind specific DNA sequences to gently switch certain genes on or off, particularly genes involved in immunity and cell growth. In laboratory studies it appears to 'unwind' certain compacted regions of chromatin in cells from elderly people, reawakening some silenced genes, while leaving other regions untouched. In animals it has been reported to stimulate immune tissue, tune inflammatory signaling, prolong lifespan, and reduce the development of tumors. Importantly, the DNA-binding/epigenetic story is based mostly on computer modeling and cell-culture work, not confirmed in humans, and almost all of the evidence comes from a single research group.

Overview

Overview

Vilon (also called the KE peptide or Lys-Glu dipeptide) is a synthetic dipeptide composed of L-lysine and L-glutamic acid (Lys-Glu, abbreviated KE). It has a molecular weight of approximately 275.30 g/mol, the molecular formula C11H21N3O5, and CAS number 45234-02-4. It is described as among the shortest known biologically active peptides — the shortest bioactive peptide in the Khavinson bioregulator program.

Origin

Vilon was developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, first synthesized in the 1970s as part of a Soviet-era peptide bioregulator program. It was originally identified as one of three principal active components of Thymalin, the bovine thymic extract that became the first peptide bioregulator preparation approved in the USSR (1982).

Proposed Mechanism

According to its developers, Vilon's small size allows it to enter cell nuclei, bind sequence-specific sites in gene-promoter DNA, and remodel chromatin to selectively modulate expression of immune- and proliferation-related genes. This proposed DNA-binding/epigenetic mechanism is model-based (molecular docking) and not clinically confirmed. Molecular docking identified GCGC as the preferred double-stranded DNA sequence (in the curved nucleosomal form), and cluster analysis nominated genes encoding AKT1/AKT2 — proteins implicated in cytokine-storm development — as potential targets.

In cultured lymphocytes from elderly donors (age 75–88), Vilon induced deheterochromatinization (decondensation) of total facultative heterochromatin, reactivated ribosomal genes, and released age-silenced genes — an effect that increased progressively with donor age. Notably, it did not decondense pericentromeric structural heterochromatin, indicating selective, region-specific effects. In mesenchymal stem cells it regulated IGF1, FOXO1, TERT, and NFkB; in the THP-1 monocyte/macrophage line it produced modest, receptor-independent shifts in proliferative and inflammatory gene programs. A bioinformatic analysis of 20,417 UniProt proteins found KE motifs enriched in cytoplasmic and nuclear proteins and minimal in membrane proteins, supporting a model in which KE released during proteolysis binds DNA to regulate transcription.

Preclinical Findings

Decades of predominantly preclinical (largely Russian-language) research have investigated Vilon's effects on immune function, lifespan, tumor prevention, and cardiovascular gene expression:

  • Immune: KE stimulates cellular immunity and nonspecific resistance, activating macrophages, blood lymphocytes, thymocytes, and neutrophils. It stimulated thymus explant growth in organotypic culture and promoted immune-cell differentiation. Rodent studies reported improved CD4/CD8 ratios and innate immune markers.
  • Anti-inflammatory: In an in vitro inflammatory model, Thymalin and its EW and KE dipeptides reduced synthesis of IL-1β, IL-6, and TNF-α in human peripheral blood mononuclear cells by 1.4–6.0 times.
  • Geroprotection: In female CBA mice, subcutaneous Vilon from the 6th month of life increased physical activity and endurance, decreased body temperature, prolonged lifespan, and prevented spontaneous neoplasms — but had no effect on age-related estrous changes or free-radical processes.
  • Oncostatic: At 10 µg/kg, Vilon reduced tumor development in a 1,2-dimethylhydrazine model to 14.3% vs 60% in controls and inhibited preneoplastic kidney changes; it decreased urinary bladder tumor incidence in a nitrosamine rat model (56% vs 75.5%); and at 1 mg/kg increased survival of mice with transplanted Lewis lung carcinoma.
  • Other: Oral administration for 1 month improved small-intestine glucose transport in aged rats. In mouse heart, Vilon altered expression of a small fraction of a cDNA library, with broader changes when combined with Epithalon.

Human Data & Positioning

Human data are limited to ex vivo studies of aged lymphocyte chromatin and one group's cohort follow-up. Khavinson's group has published 12-year follow-up cohort data reporting reduced mortality in elderly subjects taking annual Vilon + Thymalin cycles, and has claimed telomerase upregulation in immune cell lines — both from a single group without independent replication. Vilon is studied and positioned as an immune modulator, claimed geroprotector, and immune-targeted short bioregulator, sometimes paired with Thymalin for claimed synergistic effects on T-cell maturation and innate immunity. Thymalin itself (whose active substances include KE and EW) has reported efficacy in acute respiratory distress syndrome, COPD, and complex therapy of severe COVID-19 in middle-aged and elderly patients.

Important Limitations

Nearly all Vilon evidence comes from one research program with little independent replication, predominantly in Russian-language literature. There are no human randomized controlled trials and no approved indications. The DNA-binding/chromatin mechanism is model-based, not clinically confirmed. Oral bioavailability of the intact dipeptide is proposed on the basis of its small size but has not been demonstrated in formal pharmacokinetic studies.

What the research shows

102 findings extracted from the 20 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 3 human study findings, 14 animal findings, 1 in vitro finding, 3 expert opinion findings and 1 theoretical finding.

  • human studyThymalin is an immunomodulatory drug containing a polypeptide extract of thymus that has demonstrated efficacy in the therapy of acute respiratory distress syndrome and chronic obstructive pulmonary disease, as well as in complex therapy related to severe COVID-19 in middle-aged and elderly patients5

  • human studyPersistence and adherence in anti-obesity drug use are low18

  • human studyPersistence and compliance in anti-obesity drug use can be significantly increased by reducing the dosing frequency18

  • animalVilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors in mice2

  • animalVilon increases life span of mice2

  • animalAfter vilon treatment at 10 microg/kg, tumors developed in 14.3% of mice that survived until first tumor detection at 46 weeks8

  • animalIn control group, tumors occurred in 60%8

  • animalVilon-related inhibition of preneoplastic alterations in the kidneys was reported8

Show 14 more findings

  • animalInjections of synthetic peptide vilon at the doses 1 mg/kg significantly increased the survival of mice with transplanted Lewis lung carcinoma10

  • animalVilon (Lys-Glu) decreased the incidence of urinary bladder tumors in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine carcinogen13

  • animalVilon significantly inhibited carcinogenesis in urinary bladder13

  • animalSubcutaneous administration of vilon (Lys-Glu) to female CBA mice starting from the 6th month of life increased physical activity and endurance15

  • animalVilon decreased body temperature in female CBA mice15

  • animalVilon prolonged the lifespan in female CBA mice15

  • animalVilon prevented the development of spontaneous neoplasms in female CBA mice15

  • animalVilon had no effect on age-related changes of estrous function in female CBA mice15

  • animalVilon had no effect on free radical processes in female CBA mice15

  • in vitroAn in vitro model of an inflammatory reaction demonstrated that Thymalin and EW and KE dipeptides reduced the synthesis of IL-1β, IL-6, and TNF-α cytokines in human peripheral blood mononuclear cells by 1.4-6.0 times5

  • expert opinionPeptides demonstrate effective target engagement and clinically meaningful efficacy3

  • expert opinionDisease-specific therapeutic applications including tumor regression, metabolic regulation, neuroprotection, and immune modulation have demonstrated beneficial effect3

  • expert opinionVilon is showing remarkable promise in experimental biology and longevity research16

  • theoreticalPeptide KE exhibits immunoprotective, geroprotective, and oncostatic activities6

How it works

Based on 3 human study findings, 13 animal findings, 16 in vitro findings, 10 expert opinion findings and 14 theoretical findings.

  • human studyPeptide bioregulator Lys-Glu (Vilon) induces deheterochromatinization (decondensation) of total heterochromatin in lymphocytes from 75-88-year-old individuals4

  • human studyVilon activates synthetic processes of ribosomal genes without causing deheterochromatinization of pericentromeric structural heterochromatin4

  • human studyVilon has selective effects on definite regions of chromosomes, inducing selective remodeling of facultative heterochromatin4

  • animalVilon has antineoplastic (anti-tumor) pharmacology2

  • animalKE stimulates cellular immunity and nonspecific resistance in organisms, exerting an activating effect on macrophages, blood lymphocytes, thymocytes, and neutrophils5

  • animalVilon possesses oncomodulating action on transplanted carcinoma10

  • animalVilon enhanced passive glucose accumulation in the serous fluid in inverted sac made from the distal region of the small intestine11

  • animalVilon stimulated active glucose accumulation in the serous sac of the medial small intestine11

Show 48 more findings

  • animalVilon changed expression of 36 clones out of 15,247 total clones from a cDNA library in mouse heart12

  • animalVilon alone or in combination with Epithalon activated expression of 157 clones (maximally by 6.13 times)12

  • animalVilon alone or in combination with Epithalon inhibited expression of 23 clones (maximally by 2.79 times)12

  • animalCombined treatment with Vilon and Epithalon changed expression of 144 clones12

  • animalVilon has specific effects on gene expression12

  • animalVilon 2-fold decreased the incidence of preneoplastic and early neoplastic changes in urinary bladder mucosa13

  • animalVilon stimulated the growth of explants from thymus in organotypic cultures14

  • animalVilon produced tissue-specific effects, stimulating growth of explants from tissues whose cytomedins (peptide complexes) were used for chemical synthesis14

  • in vitroNew strategy for enhancing the in vivo half-life of peptides without compromising their potency1

  • in vitroUsing molecular docking, GGAG was found to be the best dsDNA sequence in the classical B-form for binding the EW dipeptide, while GCGC is the preferred dsDNA sequence in the curved nucleosomal form for the KE dipeptide5

  • in vitroCluster analysis revealed that potential target genes for the EW and KE peptides encode the AKT1 and AKT2 proteins involved in the development of the cytokine storm5

  • in vitroThe levels of KE motifs were maximum in cytoplasmic and nuclear proteins6

  • in vitroThe presence of KE in the membrane and all other proteins was the minimum6

  • in vitroVilon activates synthetic processes, caused by reactivation of ribosomal genes as a result of deheterochromatinization (decondensation) of nucleolus organizer regions7

  • in vitroVilon induces unrolling (deheterochromatinization) of total heterochromatin7

  • in vitroVilon releases genes repressed by heterochromatinization (condensation) of euchromatic regions forming facultative heterochromatin7

  • in vitroVilon does not induce deheterochromatinization of pericentromeric structural heterochromatin7

  • in vitroVilon causes activation (deheterochromatinization) of chromatin in lymphocytes of old individuals7

  • in vitroVilon induces unrolling (deheterochromatinization) of total heterochromatin9

  • in vitroVilon activates synthetic processes caused by the reactivation of ribosomal genes as a result of deheterochromatinization of nucleolus organizer regions9

  • in vitroVilon releases genes repressed due to the condensation of euchromatic regions forming facultative heterochromatin9

  • in vitroVilon does not induce decondensation of pericentromeric structural heterochromatin9

  • in vitroVilon stimulated apoptosis in spleen organotypic tissue culture in both young and old rats10

  • in vitroThe inhibitory effect of cyclophosphan was abolished in the presence of vilon in culture media at the dose 5 ng/ml10

  • expert opinionVilon is a tiny dipeptide (Lys-Glu)16

  • expert opinionPeptides exhibit unique and powerful pharmacology that has not been possible to effectively mimic with either small molecules or antibodies17

  • expert opinionPEGylation was one of the first chemical modification techniques shown to increase peptide half-life by decreasing the rate of renal filtration17

  • expert opinionLipidation has been utilised to extend peptide half-life17

  • expert opinionClassical genetic fusions offer advantages in terms of half-life but also their own severe constraints in terms of drug design17

  • expert opinionPEGylation can make proteins or peptides more water-soluble and protect them from degradation by proteolytic enzymes17

  • expert opinionPEGylation can reduce the affinity of therapeutic proteins to their cognate cellular receptors17

  • expert opinionPEG is attached to the -amino groups of lysine on the surface of proteins or peptides17

  • expert opinionAt high pH (8.0 or higher), lysine side chain amino groups are covalently attached to PEG through N-hydroxy succinimides17

  • expert opinionThe most common half-life extension technologies used for peptides include lipidation, PEGylation, and Fc fusions, all of which allow only weekly administration18

  • theoreticalVilon is a synthetic dipeptide2

  • theoreticalPeptides interact with specific receptors to elicit highly selective biological responses3

  • theoreticalPeptides often demonstrate higher specific activity per unit mass, approximately 15-60 times that of antibodies, due to their lower molecular weight and more efficient receptor engagement3

  • theoreticalKE and EW dipeptides are active substances of Thymalin5

  • theoreticalEW reduces angiotensin-induced vasoconstriction and preserves endothelium-dependent vascular relaxation by inhibiting ACE2, the target protein of SARS-CoV-25

  • theoreticalPeptide KE stimulates functional activity of fibroblasts6

  • theoreticalThe KE motif is present in amino acid sequences of some cytokines and peptide hormones functionally similar to KE peptide6

  • theoreticalKE peptide molecules released from nuclear proteins during limited proteolysis can bind to DNA and regulate gene expression6

  • theoreticalThe optimal half-life is about equal to the dosing interval18

  • theoreticalThe assembly of peptides is generally mediated by liquid-liquid phase separation, which enables control over assembly kinetics, final structure, and functions of peptide-based supramolecular materials.19

  • theoreticalModulating phase separation can alter the assembly kinetics of peptides by changing solvents or introducing external fields.19

  • theoreticalThe assembly of peptides can be effectively catalyzed by complex coacervates.19

  • theoreticalNegatively charged sodium alginate (SA) can form complex coacervates with the positively charged KLVFFAE (Aβ, abbreviated as KE) peptide, thereby lowering the nucleation barrier and promoting the assembly of the peptide.19

  • theoreticalAs the binding affinity of SA-KE and the dosage of SA decrease, the system shifts from a relatively inefficient template-induced assembly to a highly efficient catalytic assembly before ultimately reverting to slow spontaneous assembly.19

How the body handles it

Based on 5 expert opinion findings and 1 theoretical finding.

  • expert opinionChallenges remain in improving peptide stability and delivery3

  • expert opinionShort half-lives resulting from sensitivity to proteases and rapid renal clearance mean that peptide drugs tend to require frequent doses17

  • expert opinionPEGylation improved the pharmacokinetics of proteins even in the absence of anti-drug antibodies17

  • expert opinionIncreasing size or hydrodynamic radius led to reduced renal clearance and increased half-life17

  • expert opinionAMG133 – a GLP-1 agonist/GIP antagonist mAb – has a half-life of 14 days yet is dosed every month18

  • theoreticalAll peptides have short in vivo half-lives of minutes to hours and require some form of half-life extension to make them practical for use as therapeutics18

Safety and side effects

Based on 2 human study findings, 3 animal findings and 1 expert opinion finding.

  • human studyThe GI toxicity of GLP-1 agonists is related to dosing frequencies in the order twice daily (BID) > daily (QD) > weekly (QWk)18

  • human studyGI effects are less common with long-acting than short-acting compounds18

  • animalSynchronous injection of both vilon and cyclophosphan at the doses 100 mg/kg decreases the survival of mice10

  • animalLong-term administration of vilon caused no unfavourable effects on animal development15

  • animalResults show safety of chronic vilon administration15

  • expert opinionPeptides generally demonstrate favorable safety profiles with minimal adverse events3

What people use it for

Based on 3 animal findings, 1 in vitro finding, 6 expert opinion findings and 1 theoretical finding.

  • animalVilon (Lys-Glu) influences 1.2-dimethylhydrazine-induced neoplasia in mice8

  • animalVilon and cytostatic drugs must not be used synchronously in cancer therapy10

  • animalVilon (Lys-Glu) administered orally for 1 month improved transport characteristics of the small intestine in aged rats11

  • in vitroVilon causes progressive activation (deheterochromatinization) of the facultative heterochromatin with increased aging9

  • expert opinionShort peptide bioregulators like Vilon open up new opportunities in the treatment of aging diseases through chromosome region remodeling4

  • expert opinionVilon could help regulate immunity16

  • expert opinionVilon could help regulate gene expression16

  • expert opinionVilon could help regulate cellular aging16

Show 3 more findings

  • expert opinionVilon could help with tissue regeneration16

  • expert opinionPeptides suffer from drawbacks, in particular, the lack of oral bioavailability which necessitates injections17

  • theoreticalProdrugs of low-clearance GLP-1 agonists could produce ultralong-acting agonists with dosing intervals reaching 3 to even 6 months18

Other findings

Based on 1 animal finding.

  • animalVilon composition is Lys-Glu11

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Single source

Nearly all Vilon evidence comes from one research program with little independent replication.

Multiple sources note the evidence is dominated by Khavinson's institutional network, predominantly in Russian-language literature, with essentially no independent Western replication of efficacy or safety data.

Limited evidence

No human randomized controlled trials or approved indications exist for Vilon.

Sources agree there are no large controlled human trials, no registered/published human clinical trials, and no approved indication; human data is limited to in vitro studies on cells from elderly donors and one group's cohort follow-up. The bulk of efficacy data is animal and cell-culture.

Contested

Reported half-life estimates conflict (minutes vs ~1.2 hours).

One source states the plasma half-life is expected to be very short, on the order of minutes (theoretical), while another reports an elimination half-life of 1.2 ± 0.4 hours after IV dosing. No robust human PK data reconciles these.

Limited evidence

Oral bioavailability is proposed but not demonstrated.

Sources note the small ~275 Da size is claimed to enable potential oral bioavailability, but also explicitly state oral bioavailability of intact vilon has not been demonstrated in formal pharmacokinetic studies.

Limited evidence

The DNA-binding/chromatin mechanism is model-based, not clinically confirmed.

The proposed nuclear entry, sequence-specific DNA binding, and epigenetic gene modulation rest largely on molecular docking and cell-culture/ex vivo work, and are described as not clinically confirmed.

Single source

Claims of telomerase upregulation and reduced-mortality cohort data come from a single group.

The telomerase upregulation claim and the 12-year follow-up cohort reporting reduced mortality with Vilon+Thymalin derive from Khavinson's group only, without independent replication.

Using it with other compounds

Check a stack
  • ElafinComplementary

    No documented conflict

    Vilon is an immunomodulatory bioregulator that suppresses inflammatory cytokines and normalizes immune ratios, overlapping with elafin's anti-inflammatory NF-κB modulation but acting through different (gene-regulatory) mechanisms.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory · NF kB modulation

  • ImunofanSame downstream effect

    Worth caution

    Vilon is a Khavinson bioregulator that improves CD4/CD8 ratio, stimulates thymic/immune cell differentiation and suppresses TNF/IL-6, reaching the same immune-normalizing endpoint as imunofan but via a proposed gene/chromatin route rather than thymopoietin receptors. Overlapping goals mean modest additive value at best and heavy redundancy in immune correction.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory · T cell regulation

  • KlothoComplementary

    No documented conflict

    Both are framed as geroprotective agents that lower inflammatory cytokines and modulate NF-κB, with Vilon additionally influencing IGF1/FOXO/TERT gene expression and Klotho acting as a longevity-associated, anti-senescence protein. They converge on healthy-aging endpoints through largely different mechanisms (chromatin/gene regulation vs. FGF23/antioxidant/anti-fibrotic signaling).

    Tier 4Theoretical — not established

    Shares anti inflammatory · NF kB modulation · IGF1 signaling

  • PidotimodSame downstream effect

    Worth caution

    Vilon is a Khavinson-school bioregulator reported to stimulate cellular immunity, improve CD4/CD8 ratio and enhance innate-immune markers — the same immune-enhancing goals as pidotimod but through a proposed gene/chromatin mechanism rather than TLR/dendritic-cell signaling. They overlap heavily on outcome, so combining them is more redundant than synergistic; choose based on evidence quality rather than stacking.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory · T cell regulation

  • SelankComplementary

    No documented conflict

    Selank (a tuftsin-derived peptide) carries immunomodulatory and Th1/Th2-balancing activity alongside its main anxiolytic/nootropic role. That immune-modulating side overlaps with Vilon's T-cell and cytokine effects, so the two can complement each other where both immune support and CNS/stress effects are desired.

    Tier 4Theoretical — not established

    Shares anti inflammatory · T cell regulation

  • ThymulinComplementary

    May be complementary

    Both are thymus-linked immune bioregulators that push the immune system toward balance rather than pure stimulation. Vilon is reported to stimulate thymus tissue growth and improve CD4/CD8 ratios, while thymulin drives T-lymphocyte maturation and normalizes CD4/CD8 balance from the endocrine side. They approach the same immune-normalizing endpoint by different routes, which makes them reasonably complementary for restoring aged/depleted immunity.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory · T cell regulation · NF kB modulation

  • HumaninComplementary

    No documented conflict

    Humanin is a mitochondrial-derived cytoprotective 'mitokine' with anti-inflammatory and IGF-1-related signaling; Vilon is a gene-regulatory geroprotector supporting immune and metabolic function in aged tissue. They target aging through distinct mechanisms (mitochondrial stress signaling vs. chromatin/gene reactivation) that can complement each other in a longevity-oriented approach.

    Tier 4Theoretical — not established

    Shares anti inflammatory · IGF1 signaling

  • LactoferrinComplementary

    No documented conflict

    Lactoferrin adds direct antimicrobial and innate-immune defense plus anti-inflammatory activity, while Vilon works at the gene-expression level to support T-cell/thymic immunity. Different mechanisms both reinforcing host defense, making them a reasonable complementary immune pairing.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory

  • LL-37Complementary

    Worth caution

    LL-37 is a human cathelicidin providing frontline antimicrobial and innate-immune signaling; Vilon supports adaptive/T-cell immunity via gene reactivation. They cover different arms of immunity, so they are complementary rather than redundant, though LL-37's context-dependent pro-inflammatory effects warrant monitoring.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory

  • ThymalinSame mechanism

    Worth caution

    Vilon is a Khavinson-school peptide bioregulator that, like Thymalin, is proposed to act at the gene/DNA level to normalize cellular immunity, improve CD4/CD8 ratios, and suppress IL-1/IL-6/TNF-alpha with geroprotective intent. They share the same cytomedin/bioregulator rationale and immune-normalizing endpoint, making them redundant partners rather than complementary ones.

    Tier 4Theoretical — not established
    What the research doesn't establish
    Although Thymalin and Vilon produce overlapping immune effects, they do not share the same molecular mechanism. Thymalin acts through T-cell receptors, thymic peptide binding, histone (H1/H3) and surface-marker modulation (CD28, CD44, CD117), and binds DNA at GGAG/GCGC/TCGA sites, whereas Vilon is described as receptor-independent, acting via chromatin remodeling and DNA binding at GCGC. Their shared cytokine suppression reflects convergent endpoints, not a common pathway.

    Shares innate immune · anti inflammatory · T cell regulation · NF kB modulation

  • Thymosin Alpha-1Same mechanism

    Worth caution

    Vilon is a Khavinson-school immune bioregulator that stimulates cellular immunity, improves CD4/CD8 ratios, and suppresses inflammatory cytokines — overlapping heavily with Thymosin Alpha-1's immune-restoring actions. The combination is largely redundant rather than mechanistically distinct.

    Tier 4Theoretical — not established
    What the research doesn't establish
    While both peptides share approved tags (innate_immune, anti_inflammatory, T_cell_regulation) and produce overlapping immunological effects, their underlying mechanisms are fundamentally distinct and not established as 'same mechanism.' Thymosin Alpha-1 operates through well-characterized cell-surface receptor engagement (TLR2, TLR3, TLR4, TLR7, TLR9, MHC Class I) and downstream signaling cascades (TLR/IRF3, TLR/NF-κB, MyD88, etc.). Vilon's mechanism is proposed as receptor-independent, operating instead through direct DNA binding (GCGC motif preference) and chromatin remodeling/deheterochromatinization. These are mechanistically distinct pathways—one receptor-mediated, one gene-regulatory—despite convergent immunological outcomes. Shared phenotypic effects (immune stimulation, cytokine modulation) do not establish 'same mechanism' when the described molecular mechanisms of action differ fundamentally. The claim of 'redundancy' reflects functional overlap, not mechanistic identity.

    Shares innate immune · anti inflammatory · T cell regulation

  • PinealonSame mechanism

    Worth caution

    Vilon is another ultra-short Khavinson bioregulator that, like Pinealon, is proposed to act without a membrane receptor by binding gene-promoter DNA and remodeling chromatin. They target different systems on paper (Vilon skews immune/geroprotective, Pinealon neuroprotective), but the entire underlying 'peptide binds DNA to reactivate genes' mechanism is shared and rests on modeling/in-vitro claims. Understand that combining them does not give you two independent, well-validated tools — it gives you two peptides resting on the same unproven premise.

    Tier 4Theoretical — not established

Safety and side effects

Safety Profile

Regulatory status: Vilon is not registered or approved as a pharmaceutical in any country. It is classified as research-use-only or marketed as a dietary supplement and has not been evaluated by the FDA, EMA, or other Western regulatory agencies.

Reported Tolerability

  • In long-term/chronic mouse studies, Vilon caused no unfavourable effects on animal development or estrous function and was associated with increased lifespan, reduced spontaneous tumor incidence, and improved physical parameters.
  • Adverse events were not a documented finding in Khavinson-group studies; the originators describe the entire bioregulator family as producing practically no side effects — a claim resting on a small body of preclinical work from a single Russian research lineage.
  • The most consistent community/anecdotal feedback for subcutaneous bioregulator use is mild, typically short-lived redness, itching, or tenderness at the injection site. Russian clinical literature reports rare local injection-site reactions with no serious adverse events documented at standard doses.
  • The longest published safety study for Vilon spans 12 months in rat models.

Cautions & Interactions

  • Cytostatic drug interaction: Vilon and cytostatic drugs should not be used synchronously. Synchronous injection of Vilon and cyclophosphan at 100 mg/kg decreased mouse survival. (Note that in cell culture, Vilon at 5 ng/ml abolished cyclophosphan's inhibitory effect — the interaction direction is context-dependent.)
  • Active autoimmune disease: Use during an active autoimmune flare is not well-characterized, because Vilon modulates T-cell function and the direction of effect in active autoimmunity is unknown.

Bottom Line

The absence of documented adverse events reflects a small, single-lineage evidence base rather than large, independently replicated safety trials. There are no controlled human safety data and no regulatory review to support clinical use.

Reconstitution and handling

Preparation & Dosing

No dose has been established for this compound. No regulatory label exists for it, so the figures below are what sources report — not guidance.

Important: No validated human dosing protocols exist for Vilon. All research derives from a single research group without independent replication, and Vilon is not an approved pharmaceutical anywhere. The figures below simply report what has been described in the literature and community.

Reported Routes & Doses

  • Historical Russian experimental/clinical work used short intramuscular injection courses; rodent studies used microgram-to-milligram parenteral doses.
  • Russian clinical dosing reported for immunodeficiency and post-infection recovery: 0.5–2 mg intramuscularly for 10 days.
  • Russian retail sublingual/oral dosing: drops or capsules 3–4×/day for 30 days, 3×/year.
  • Reported research/biohacker dosing: 100–200 mcg subcutaneously daily for 10–14 days, repeated 2–3 times per year.

Pharmacokinetic Considerations

  • Vilon's plasma/in vivo half-life is expected to be very short, on the order of minutes (theoretical), while one source reports an elimination half-life of ~1.2 ± 0.4 hours after IV dosing — these estimates conflict and are not reconciled by robust human PK data.
  • Peptides generally have short in vivo half-lives (minutes to hours) owing to protease sensitivity and rapid renal clearance, often prompting frequent dosing.
  • Vilon's very small size (~275 Da dipeptide) is proposed to enable potential oral bioavailability, but oral bioavailability of the intact dipeptide has not been demonstrated in formal pharmacokinetic studies — a key caveat for the sublingual/oral retail forms.

Practical Notes

As a lyophilized research peptide, injectable preparations are typically reconstituted with bacteriostatic or sterile water; however, no standardized, validated reconstitution or dosing protocol has been published. Given the single-source evidence base and lack of regulatory oversight, any use falls outside established clinical guidance.

Sources

Ordered by evidence quality — the strongest first.

  1. A biomimetic approach for enhancing the in vivo half-life of peptides - PMC(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  2. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous ...(opens in a new tab)
    Tier 2Web · pubmed.ncbi.nlm.nih.gov
  3. Safety and Efficacy of Peptide-Based Therapeutics in Health Sciences(opens in a new tab)
    Tier 2Web · biomedgrid.com
  4. EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  5. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  6. Peptide KE in Human Proteome.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  7. Anti-aging peptide bioregulators induce reactivation of chromatin.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2006
  8. [The effect of vilon (Lys-Glu) on 1.2-dimethylhydrazine-induced neoplasia].(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2005
  9. Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2004
  10. [Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age].(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2003
  11. Effect of Vilon and Epithalon on glucose and glycine absorption in various regions of small intestine in aged rats.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  12. Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  13. Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2001
  14. Tissue-specific effects of peptides.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2001
  15. Effect of vilon on biological age and lifespan in mice.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2000
  16. Healthtimes - 🧬 Vilon Peptide: The Minimalist Bioregulator...(opens in a new tab)
    Tier 3Web · facebook.com
  17. Long Live Peptides - Evolution of peptide half-life extension technologies and emerging hybrid approaches - Drug Discovery World (DDW)(opens in a new tab)
    Tier 4Web · ddw-online.com
  18. Long-Acting, Longer-Acting and Ultralong-Acting Peptides(opens in a new tab)
    Tier 4Web · preprints.org
  19. Catalytic Assembly of Peptides Mediated by Complex Coacervates.(opens in a new tab)
    Tier 4PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  20. ViLoN-a multi-layer network approach to data integration demonstrated for patient stratification.(opens in a new tab)
    Tier 4PubMed · pubmed.ncbi.nlm.nih.gov · 2023

See something wrong or out of date on this page? Report it.